相似文献
1
Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters.
Aliment Pharmacol Ther. 2022 May;55(9):1233-1234. doi: 10.1111/apt.16872.
2
Anti-TNF Therapy During the SARS-CoV-2 Pandemic: Friend or Foe?
J Crohns Colitis. 2022 May 10;16(4):517-518. doi: 10.1093/ecco-jcc/jjab167.
3
The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19.
Med. 2020 Dec 18;1(1):90-102. doi: 10.1016/j.medj.2020.11.005. Epub 2020 Dec 3.
4
Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
Aliment Pharmacol Ther. 2022 May;55(9):1235-1236. doi: 10.1111/apt.16904.
5
Role of tumor necrosis factor-α in the mortality of hospitalized patients with severe and critical COVID-19 pneumonia.
Aging (Albany NY). 2021 Nov 1;13(21):23895-23912. doi: 10.18632/aging.203663.
6
Use of Tumor Necrosis Factor Inhibitors During the COVID-19 Pandemic-Evidence in Favor of Monotherapy.
JAMA Netw Open. 2021 Oct 1;4(10):e2129707. doi: 10.1001/jamanetworkopen.2021.29707.
7
Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments.
Aliment Pharmacol Ther. 2022 Jan;55(2):154-167. doi: 10.1111/apt.16717. Epub 2021 Dec 8.
8
Tumor necrosis factor inhibitors and methotrexate are associated with decreased COVID-19-related hospitalization: Follow up of "Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors and methotrexate".
J Am Acad Dermatol. 2023 Jun;88(6):1385-1386. doi: 10.1016/j.jaad.2023.02.002. Epub 2023 Feb 10.
9
Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'.
Ann Rheum Dis. 2021 May;80(5):e79. doi: 10.1136/annrheumdis-2020-218029. Epub 2020 Aug 18.
10
[Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].
Z Rheumatol. 2020 Aug;79(6):574-577. doi: 10.1007/s00393-020-00824-0.
引用本文的文献
1
Tumour necrosis factor-alpha inhibitors decrease mortality in COVID-19: a systematic review and meta-analysis.
Crit Care. 2025 Jun 6;29(1):232. doi: 10.1186/s13054-025-05420-9.
2
Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
Aliment Pharmacol Ther. 2022 May;55(9):1235-1236. doi: 10.1111/apt.16904.
本文引用的文献
1
Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments.
Aliment Pharmacol Ther. 2022 Jan;55(2):154-167. doi: 10.1111/apt.16717. Epub 2021 Dec 8.
2
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
3
The Coronavirus Disease 2019 Pandemic's Effect on Critical Care Resources and Health-Care Providers: A Global Survey.
Chest. 2021 Feb;159(2):619-633. doi: 10.1016/j.chest.2020.09.070. Epub 2020 Sep 11.
4
Bias in meta-analysis detected by a simple, graphical test.
BMJ. 1997 Sep 13;315(7109):629-34. doi: 10.1136/bmj.315.7109.629.
5
Operating characteristics of a rank correlation test for publication bias.
Biometrics. 1994 Dec;50(4):1088-101.
Zotero 插件